Yes Bank has filed a petition in the Supreme Court against a Delhi High Court order that included the lender in a forensic audit of the Fortis Healthcare share sale. The bank maintains it was never involved in the original arbitration case between the Singh brothers and Daiichi Sankyo. This development occurs as the bank works toward a ₹16,000 crore capital raising plan to support its growth.
Yes Bank has officially moved the Supreme Court to contest a recent directive from the Delhi High Court. On August 31, 2026, the High Court ordered a forensic audit of 17 financial institutions, including Yes Bank, as part of a wider investigation into historical transactions involving Fortis Healthcare and its former promoters, Malvinder and Shivinder Singh. Yes Bank’s legal challenge seeks to exclude itself from this audit, arguing that the bank was never a party to the 2008 arbitral award proceedings that form the basis of this case.
The dispute originates from a long-running legal battle involving the Japanese pharmaceutical firm Daiichi Sankyo. The company has been seeking to enforce an arbitration award against the Singh brothers, alleging they hid critical information during the sale of Ranbaxy Laboratories in 2008. While the forensic probe aims to trace financial trails across various entities, including IHH Healthcare and the RHT Health Trust, Yes Bank has stated that it does not oppose the investigation into the former promoters or Fortis Healthcare itself. The bank’s primary objection is to the broad scope of the High Court’s order, which it believes incorrectly targets financial institutions that were not part of the original arbitration.
Impact on Bank Operations
For shareholders, this legal development adds a layer of complexity to the bank’s current operational narrative. Yes Bank has recently demonstrated solid financial momentum, reporting a net profit of ₹1,071 crore for the first quarter of fiscal year 2027, marking a 33.7% growth compared to the same period last year. The management is currently focused on a significant capital raising plan of up to ₹16,000 crore, consisting of ₹7,500 crore in equity and ₹8,500 crore in debt. This capital is intended to strengthen the balance sheet and support future lending activities.
While the forensic audit order does not impose direct financial penalties on the bank, the ongoing litigation introduces potential risks that investors may monitor. Legal uncertainty can sometimes lead to reputational pressure or market volatility. Additionally, the bank must navigate the execution of its large-scale capital raising plans against a backdrop of competitive interest rates and the need to maintain strong investor confidence. The bank has emphasized that its past transactions were compliant with regulatory frameworks and prior court orders, signaling that it intends to remain cooperative where required while defending its position against what it deems an overly broad audit mandate.
Moving forward, the primary focus for stakeholders will be the Supreme Court’s response to the bank’s petition. Any clarification regarding the scope of the forensic audit or the exclusion of financial institutions will be a key signal for the market. Investors may also track management commentary during upcoming investor calls regarding the progress of the ₹16,000 crore capital raise and whether the legal proceedings have any impact on the timeline for these funding efforts.